Construction of Bordetella pertussis strains with enhanced production of genetically-inactivated Pertussis Toxin and Pertactin by unmarked allelic exchange

BMC Microbiology

Volumn 12, Issue , 2012, Pages

  Buasri, Wasin ^a   Impoolsup, Attawut ^a   Boonchird, Chuenchit ^a   Luengchaichawange, Anocha ^b   Prompiboon, Pannipa ^b   Petre, Jean ^b   Panbangred, Watanalai ^a,c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Bionet Asia Co Ltd   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

PERTACTIN; PERTUSSIS TOXIN; PLASMID VECTOR; BACTERIAL ANTIGEN; BORDETELLA VIRULENCE FACTOR; OUTER MEMBRANE PROTEIN; PERTUSSIS TOXIN, S1 SUBUNIT; PERTUSSIS VACCINE;

ANIMAL CELL; ARTICLE; BACTERIAL CHROMOSOME; BACTERIAL GENE; BACTERIAL STRAIN; BORDETELLA PERTUSSIS; CHO CELL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC STABILITY; HOMOLOGOUS RECOMBINATION; NONHUMAN; ANIMAL; GENE EXPRESSION REGULATION; GENE VECTOR; GENETIC ENGINEERING; GENETICS; HAMSTER; METHODOLOGY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; SITE DIRECTED MUTAGENESIS;

BORDETELLA PERTUSSIS; CRICETULUS GRISEUS;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BASE SEQUENCE; BORDETELLA PERTUSSIS; CHO CELLS; CRICETINAE; GENETIC ENGINEERING; GENETIC VECTORS; HOMOLOGOUS RECOMBINATION; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; MUTAGENESIS, SITE-DIRECTED; PERTUSSIS TOXIN; PERTUSSIS VACCINE; VIRULENCE FACTORS, BORDETELLA;

EID: 84859928974     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-12-61     Document Type: Article

References (34)

1. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Mattoo S, Cherry JD, Clin Microbiol Rev 2005 18 326 382 10.1128/CMR.18.2.326-382.2005 15831828 (Pubitemid 40548297)
2. Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine. Aristegui J, Usonis V, Coovadia H, Riedemann S, Win KM, Gatchalian S, Bock HL, Int J Infect Dis 2003 7 143 151 10.1016/S1201-9712(03)90011-7 12839717 (Pubitemid 36753521)
3. Pertussis immunisation and serious acute neurological illness in children. Miller DL, Ross EM, Alderslade R, Bellman MH, Rawson NS, Br Med J (Clin Res Ed) 1981 282 1595 1599 10.1136/bmj.282.6276.1595 (Pubitemid 11098224)
4. Benefits and risks of immunization against pertussis. Stuart-Harris C, Dev Biol Stand 1979 43 75 83 520687 (Pubitemid 10250889)
5. Development of acellular pertussis vaccines. Sato Y, Sato H, Biologicals 1999 27 61 69 10.1006/biol.1999.0181 10600185
6. Pertussis vaccine trials. Trial synopses. Brown B, Greco D, Mastrantonio P, Salmaso S, Wassilak S, Dev Biol Stand 1997 89 37 47 9333567
7. Expression of pertussis toxin correlates with pathogenesis in Bordetella species. Monack D, Munoz JJ, Peacock MG, Black WJ, Falkow S, J Infect Dis 1989 159 205 210 10.1093/infdis/159.2.205 2464653 (Pubitemid 19049358)
8. Virulence factors of Bordetella pertussis. Weiss AA, Hewlett EL, Annu Rev Microbiol 1986 40 661 686 10.1146/annurev.mi.40.100186.003305 2877614
9. Mouse-protecting and histamine-sensitizing activities of pertussigen and fimbrial hemagglutinin from Bordetella pertussis. Munoz JJ, Arai H, Cole RL, Infect Immun 1981 32 243 250 6260681 (Pubitemid 11156929)
10. Engineering of genetically detoxified pertussis toxin analogs for development of a recombinant whooping cough vaccine. Loosmore SM, Zealey GR, Boux HA, Cockle SA, Radika K, Fahim RE, Zobrist GJ, Yacoob RK, Chong PC, Yao FL, et al. Infect Immun 1990 58 3653 3662 2228237 (Pubitemid 20353366)
11. Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough. Nencioni L, Pizza M, Bugnoli M, De Magistris T, Di Tommaso A, Giovannoni F, Manetti R, Marsili I, Matteucci G, Nucci D, et al. Infect Immun 1990 58 1308 1315 2323818 (Pubitemid 20151793)
12. Mutants of pertussis toxin suitable for vaccine development. Pizza M, Covacci A, Bartoloni A, Perugini M, Nencioni L, De Magistris MT, Villa L, Nucci D, Manetti R, Bugnoli M, et al. Science 1989 246 497 500 10.1126/science.2683073 2683073 (Pubitemid 19273940)
13. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, Ciofi degli Atti ML, Giammanco A, Panei P, Blackwelder WC, et al. N Engl J Med 1996 334 341 348 10.1056/NEJM199602083340601 8538704 (Pubitemid 26053148)
14. Protective surface antigen P69 of Bordetella pertussis: its characterization and very high level expression in Escherichia coli. Makoff AJ, Oxer MD, Ballantine SP, Fairweather NF, Charles IG, Biotechnology (N Y) 1990 8 1030 1033 10.1038/nbt1190-1030
15. Recombinant Bordetella pertussis pertactin (P69) from the yeast Pichia pastoris: high-level production and immunological properties. Romanos MA, Clare JJ, Beesley KM, Rayment FB, Ballantine SP, Makoff AJ, Dougan G, Fairweather NF, Charles IG, Vaccine 1991 9 901 906 10.1016/0264-410X(91)90011-T 1811375
16. Expression and immunological properties of the five subunits of pertussis toxin. Nicosia A, Bartoloni A, Perugini M, Rappuoli R, Infect Immun 1987 55 963 967 3549567 (Pubitemid 17035433)
17. Localization of the promoter for the ptl genes of Bordetella pertussis, which encode proteins essential for secretion of pertussis toxin. Kotob SI, Hausman SZ, Burns DL, Infect Immun 1995 63 3227 3230 7622254
18. High-level expression of tetanus toxin fragment C in Pichia pastoris strains containing multiple tandem integrations of the gene. Clare JJ, Rayment FB, Ballantine SP, Sreekrishna K, Romanos MA, Biotechnology (N Y) 1991 9 455 460 10.1038/nbt0591-455
19. Isolation and characterization of Corynebacterium diphtheriae nontandem double lysogens hyperproducing CRM197. Rappuoli R, Appl Environ Microbiol 1983 46 560 564 6416165 (Pubitemid 13024763)
20. Construction of Bordetella pertussis strains that overproduce genetically inactivated pertussis toxin. Zealey GR, Loosmore SM, Yacoob RK, Cockle SA, Herbert AB, Miller LD, Mackay NJ, Klein MH, Appl Environ Microbiol 1992 58 208 214 1539974
21. Hybrid genes over-express pertactin from Bordetella pertussis. Loosmore SM, Yacoob RK, Zealey GR, Jackson GE, Yang YP, Chong PS, Shortreed JM, Coleman DC, Cunningham JD, Gisonni L, et al. Vaccine 1995 13 571 580 10.1016/0264-410X(94)00015-F 7483778
22. Use of conditionally counterselectable suicide vectors for allelic exchange. Stibitz S, Methods Enzymol 1994 235 458 465 8057916
23. Heptakis(2,6-O-dimethyl)beta-cyclodextrin: a novel growth stimulant for Bordetella pertussis phase I. Imaizumi A, Suzuki Y, Ono S, Sato H, Sato Y, J Clin Microbiol 1983 17 781 786 6306047 (Pubitemid 13089648)
24. Effect of heptakis (2,6-O-dimethyl) beta-cyclodextrin on the production of pertussis toxin by Bordetella pertussis. Imaizumi A, Suzuki Y, Ono S, Sato H, Sato Y, Infect Immun 1983 41 1138 1143 6309661 (Pubitemid 13049293)
25. Rapid purification of pertussis toxin (PT) and filamentous hemagglutinin (FHA) by cation-exchange chromatography. Ozcengiz E, Kilinc K, Buyuktanir O, Gunalp A, Vaccine 2004 22 1570 1575 10.1016/j.vaccine.2003.09.040 15063583 (Pubitemid 38446936)
26. Method for isolating and purifying Bordetella pertussis antigenic factors. Capiau C, Desmons P, In Book Method for isolating and purifying Bordetella pertussis antigenic factors (Editor ed.eds.), vol. 5391715 City: SmithKline Beecham Biologicals 1995
27. Simultaneous determination of Bordetella pertussis toxin and filamentous haemagglutinin concentrations by hydroxyapatite high-performance liquid chromatography. Chong P, Jackson G, Cwyk W, Klein M, J Chromatogr 1990 512 227 236 2172264
28. Induction of a novel morphological response in Chinese hamster ovary cells by pertussis toxin. Hewlett EL, Sauer KT, Myers GA, Cowell JL, Guerrant RL, Infect Immun 1983 40 1198 1203 6682833 (Pubitemid 13103175)
29. Functional expression of the cre-lox site-specific recombination system in the yeast Saccharomyces cerevisiae. Sauer B, Mol Cell Biol 1987 7 2087 2096 3037344
30. Expression of the Bordetella pertussis P.69 pertactin adhesin in Escherichia coli: fate of the carboxy-terminal domain. Charles I, Fairweather N, Pickard D, Beesley J, Anderson R, Dougan G, Roberts M, Microbiology 1994 140 Pt 12 3301 3308 7881548
31. Improved pertussis toxin production by Bordetella pertussis through adjusting the growth medium's ionic composition. Frohlich BT, De Bernardez Clark ER, Siber GR, Swartz RW, J Biotechnol 1995 39 205 219 10.1016/0168-1656(95) 00013-G 7766402
32. A simple chemically defined medium for the production of phase I Bordetella pertussis. Stainer DW, Scholte MJ, J Gen Microbiol 1970 63 211 220 4324651
33. Pertactin is required for Bordetella species to resist neutrophil-mediated clearance. Inatsuka CS, Xu Q, Vujkovic-Cvijin I, Wong S, Stibitz S, Miller JF, Cotter PA, Infect Immun 2010 78 2901 2909 10.1128/IAI.00188-10 20421378
34. Capiau C, Carr SA, Hemling ME, Pl ainchamp D, Conrath K, Hauser P, Simoen E, Comberbach M, Roelants P, Desmons P, et al. Purification, characterization, and immunological evaluation of the 69-kDa outer membrane protein of Bordetella pertussis Proceedings of the sixth international symposium on pertussis. Bethesda, Md.: Department of Health and Human Services, United States Public Health Service, Food and Drug Administration 1990 75 85